Final Q-Sub Guidance Describes FDA Meeting Policy
Executive Summary
A new final guidance document from the US FDA explains how the agency wants device developers to use its Q-Submission Program to get agency feedback outside the formal product submission process.
You may also be interested in...
Digital Health Center Of Excellence Publishes Policy FAQs
The DHCoE’s new page provides a one-stop-shop for frequently asked digital health policy questions.
FDA Tweaks Q-Sub Meeting Guidance
The revised guidance document clarifies the Q-submission meeting process, alternate ways sponsors may obtain FDA feedback, and more.
US FDA Invites Comments On How It Collects Device Info Through Q-Sub Program
The US agency’s Q-Submission Program provides medical device manufacturers the opportunity to receive information on the regulatory process related to devices in development.